← Scroll for more →
Acadia Pharmaceuticals Inc (ACAD)
Pharmaceutical Preparations
Latest Price
$20.15
TTM P/E
9.04
Normalized P/E
50.91
Div Yield
--
Book Value
7.63
P/B Ratio
2.64
Valuation metrics
adjust assumptions →EPS: $2.30
Book value / share: $7.21
Formula: √(22.5 × EPS × BVPS)
Graham Number
$19.31
4% downside
Base FCF: $105M (median of recent 5yr)
Growth: 5%/yr (median YOY, capped at 25%)
Discount rate: 10%
Terminal growth: 3%
Projection horizon: 10 years
DCF Fair Value
$11.57
43% downside
EPS: $2.30
Target P/E: 51×
Formula: EPS × P/E
P/E Fair Value
$117.30
+482% upside
Institutional Ownership
96.9% held by institutions| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP | 42.91M | $1.08B | 24.93% | +16.2K | 2026-06-30 |
| BlackRock, Inc. | 22.52M | $569.0M | 13.08% | +964.3K | 2026-06-30 |
| State Street Corp | 9.08M | $229.0M | 5.27% | +743.4K | 2026-06-30 |
| Vanguard Portfolio Management LLC | 8.84M | $223.0M | 5.13% | +166.8K | 2026-06-30 |
| Rtw Investments, LP | 7.14M | $180.0M | 4.15% | -- | 2026-06-30 |
| Vanguard Capital Management LLC | 5.76M | $145.0M | 3.35% | +102.3K | 2026-06-30 |
| Dimensional Fund Advisors LP | 3.69M | $93.0M | 2.15% | +539.8K | 2026-06-30 |
| Geode Capital Management, LLC | 3.36M | $84.0M | 1.95% | -106.6K | 2026-06-30 |
| Goldman Sachs Group Inc | 2.58M | $65.0M | 1.50% | +1.02M | 2026-06-30 |
| Point72 Asset Management, L.P. | 2.46M | $62.0M | 1.43% | -143.7K | 2026-06-30 |